‘Encouragingly, all these schedules generated antibody concentrations above that of the licensed and effective two dose Oxford-AstraZeneca schedule. When it comes to cellular immunity, having a first dose of the Oxford-AstraZeneca vaccine followed by any of the other study vaccines generates a particularly robust response. The continued effort from everyone within the study helps to gather more important information on the immune response of vaccine dose combinations. ‘This is extremely encouraging and valuable data on the potential to mix-and-match COVID-19 vaccines in primary immunisation schedules. In September, the programme was further expanded to test multiple options for second dose COVID-19 vaccines in young people aged 12 to 16 years.
